Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3919157rdf:typepubmed:Citationlld:pubmed
pubmed-article:3919157lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:3919157lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:3919157lifeskim:mentionsumls-concept:C0221198lld:lifeskim
pubmed-article:3919157lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:3919157lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:3919157lifeskim:mentionsumls-concept:C0205386lld:lifeskim
pubmed-article:3919157lifeskim:mentionsumls-concept:C0599861lld:lifeskim
pubmed-article:3919157pubmed:issue4lld:pubmed
pubmed-article:3919157pubmed:dateCreated1985-4-24lld:pubmed
pubmed-article:3919157pubmed:abstractTextThe ability of neurotoxic substances to induce selective lesions of the descending monoaminergic pathways in rats was investigated. Saline, 6-hydroxydopamine, 5,6-dihydroxytryptamine, or 5,7-dihydroxytryptamine were administered into the lumbar subarachnoid space through a chronically indwelling catheter. The lesions were evaluated 2-3 weeks later by in vitro uptake of [3H]noradrenaline and [14C]5-hydroxytryptamine into synaptosomal preparations from the frontal cortex, brainstem, cervical spinal cord, and lumbar spinal cord of each animal. There was no difference in uptake between saline-injected and noncatheterized controls and no significant changes in cortical uptake after any of the treatments (dose range of neurotoxins: 0.6-80 micrograms). In the lumbar spinal cord, 6-hydroxydopamine (5-80 micrograms) reduced the [3H]noradrenaline uptake by approximately 90% with no effects on [14C]5-hydroxytryptamine uptake, whereas 5,6-dihydroxytryptamine reduced the uptake of [14C]5-hydroxytryptamine by 90% (20-80 micrograms). [3H]Noradrenaline uptake was unaffected by lower doses of 5,6-dihydroxytryptamine but fell by 45-55% after 40-80 micrograms. 5,7-Dihydroxytryptamine (10-80 micrograms) reduced [3H]noradrenaline uptake by 90-95% and [14C]5-hydroxytryptamine uptake by approximately 80% (5-80 micrograms) in the lumbar cord. It is concluded that intrathecal administration of suitable doses of neurotoxins may produce extensive selective lesions of descending noradrenergic and serotonergic pathways.lld:pubmed
pubmed-article:3919157pubmed:languageenglld:pubmed
pubmed-article:3919157pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3919157pubmed:citationSubsetIMlld:pubmed
pubmed-article:3919157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3919157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3919157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3919157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3919157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3919157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3919157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3919157pubmed:statusMEDLINElld:pubmed
pubmed-article:3919157pubmed:monthAprlld:pubmed
pubmed-article:3919157pubmed:issn0022-3042lld:pubmed
pubmed-article:3919157pubmed:authorpubmed-author:HoltDDlld:pubmed
pubmed-article:3919157pubmed:authorpubmed-author:BergeO GOGlld:pubmed
pubmed-article:3919157pubmed:authorpubmed-author:FasmerO BOBlld:pubmed
pubmed-article:3919157pubmed:authorpubmed-author:TveitenLLlld:pubmed
pubmed-article:3919157pubmed:issnTypePrintlld:pubmed
pubmed-article:3919157pubmed:volume44lld:pubmed
pubmed-article:3919157pubmed:ownerNLMlld:pubmed
pubmed-article:3919157pubmed:authorsCompleteYlld:pubmed
pubmed-article:3919157pubmed:pagination1156-61lld:pubmed
pubmed-article:3919157pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:meshHeadingpubmed-meshheading:3919157-...lld:pubmed
pubmed-article:3919157pubmed:year1985lld:pubmed
pubmed-article:3919157pubmed:articleTitleSelective neurotoxic lesions of descending serotonergic and noradrenergic pathways in the rat.lld:pubmed
pubmed-article:3919157pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3919157pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3919157lld:pubmed